The funds to support the production in Romania of several products on which Romanian and European patients depend, come as a result of a European Commission strategy, which seeks to strengthen the EU’s space in the strategic field of therapies for serious illnesses. The next step once the EUR100 million funding reaches the Iasi-based manufacturer is to start organizing tenders and work.
“We will set up a research center that will speed up the development of licenses, authorization dossiers for critical products and more. They will be made on two new production sites,” Antibiotice Iasi CEO Ioan Nani said.
(English version by Loredana Fratila-Cristescu)